摘要
目的观察齐拉西酮联合碳酸锂治疗双相障碍躁狂发作的临床疗效及安全性。方法将68例双相障碍躁狂发作患者随机分为两组,各34例,研究组口服齐拉西酮和碳酸锂,对照组口服碳酸锂治疗,观察6周。于治疗前及治疗后第2、4、6周末采用Beck-Rafaelsen躁狂量表(BRMS)评定临床疗效,以副反应量表(TESS)评定不良反应。结果在第2周末评分研究组比对照组有显著下降,在第6周末两组评分均显著下降,差异无统计学意义;两组不良反应发生差异无统计学意义。结论齐拉西酮联合碳酸锂治疗双相障碍躁狂发作起效快疗效好,不良反应轻,安全性高。
Objective To explore the efficacy and safety of quetiapine vs.Lithium carbonate in the treatment of bipolar disorder manic episode（BDME）.Methods Sixty-eight BDME patients were randomly assigned to two groups of 34 ones each,research group took orally quetiapine and control group did lithium carbonate for 6 weeks.Clinical efficacies were assessed with the Beck-Rafaelsen Mania Scale（BRMS） and Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 2nd,4th and 6nd week.Results Score of study group decreased significantly than the control group in the second week,the difference between groups was significant.Scores of two groups were significantly decreased in the 6th weeks,difference between groups was not significant,adverse reactions of two groups were no significant differences.Conclusion Ziprasidone combined with lithium is rapid onset,curative effects,less adverse reaction and higher security in treatment of manic episodes of bipolar disorder.
出处
《中国实用医药》
2011年第31期39-40,共2页
China Practical Medicine
